IPCALAB1,972.10

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹50,032 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt1,387.51,301.7703.9703.9
Net Debt620.2371.1-366.6-366.6
Total Debt/Equity0.180.160.070.07
Net Debt/Equity0.080.04-0.04-0.04
Total Debt/EBITDA1.050.750.360.36
Net Debt/EBITDA0.470.22-0.19-0.16
Interest Coverage (EBIT/Interest)6.9715.6420.5520.55
Total Debt/Total Capital %15.2213.436.886.88
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.